Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review

World Journal of Biological Psychiatry

Volumn 18, Issue 6, 2017, Pages 410-423

  Cooper, Matthew D ^a,b   Rosenblat, Joshua D ^b,c   Cha, Danielle S ^b,d   Lee, Yena ^b   Kakar, Ron ^b,e   McIntyre, Roger S ^b,c,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

adverse effects; depression; intranasal; Ketamine; psychosis

Indexed keywords

ESKETAMINE; KETAMINE; LANICEMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID MODULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; R KETAMINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; ENANTIOMER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR DEPRESSION; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBLINGUAL DRUG ADMINISTRATION; ADVERSE DRUG REACTION;

DEPRESSIVE DISORDER, MAJOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE;

EID: 84961204102     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2016.1139747     Document Type: Review

References (62)

1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. 2010. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 67:139–145.
2. Abelaira HM, Reus GZ, Neotti MV, Quevedo J., 2014. The role of mTOR in depression and antidepressant responses. Life Sci. 101:10–14.
3. Anderson PM, Pinault D, O'Brien TJ, Jones NC., 2014. Chronic administration of antipsychotics attenuates ongoing and ketamine-induced increases in cortical γ oscillations. Int J Neuropsychopharmacol. 17:1895–1904.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 47:351.
5. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR. 2013. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 38:729–742.
6. Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Manji HK, Zarate CA Jr, Drevets WC. 2013. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression:a preliminary positron emission tomography study. Biol Psychiatry. 73:1213–1221.
7. Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB., 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med. 36:71–76.
8. Correll GE, Futter GE., 2006. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 7:92–95.
9. Coyle CM, Laws KR., 2015. The use of ketamine as an antidepressant:a systematic review and meta-analysis. Hum Psychopharmacol. 30:152–163.
10. Cusin C, Hilton GQ, Nierenberg AA, Fava M., 2012. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 169:868–869.
11. De Gioannis A, De Leo D., 2014. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 48:686
12. Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R. 2014. Ketamine infusions for treatment resistant depression:a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol (Oxford). 28:536–544.
13. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 67:793–802.
14. Duman RS, Li N., 2012. A neurotrophic hypothesis of depression:role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci. 367:2475–2484.
15. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ., 2009. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 60:1439–1445.
16. Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM. 2013. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside:a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 70:668–676.
17. Harihar C, Dasari P, Srinivas JS., 2013. Intramuscular ketamine in acute depression:a report on two cases. Indian J Psychiatry. 55:186–188.
18. Hashimoto K., 2014. The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression. Clin Psychopharmacol Neurosci. 12:72–73.
19. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr. 2011. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 35:1155–1159.
20. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS. 2013. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care:a 28-day open-label proof-of-concept trial. J Palliat Med. 16:958–965.
21. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. 2006. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 163:1561–1568.
22. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey. 2003. The epidemiology of major depressive disorder:results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289:3095–3105.
23. Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK. 2014. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 15:579–584.
24. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. 2014. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biol Psychiatry. 76:970–976.
25. Lara DR, Bisol LW, Munari LR., 2013. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 16:2111–2117.
26. Larkin GL, Beautrais AL., 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 14:1127–1131.
27. Lee EE, Della Selva MP, Liu A, Himelhoch S., 2015. Ketamine as a novel treatment for major depressive disorder and bipolar depression:a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 37:178–184.
28. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, et al. 2014. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression:a 12-week double-blind, randomized controlled trial. J Clin Psychopharmacol. 34:337–343.
29. Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R., 2012. Neuropsychological and mood effects of ketamine in electroconvulsive therapy:a randomised controlled trial. J Affect Disord. 142:233–240.
30. Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richard EM, Brutsche NE, Guevara S, Zarate CA. 2014. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 159:56–61.
31. Maia-de-Oliveira JP, Lobao-Soares B, Ramalho T, Gavioli EC, Soares VP, Teixeira L, Baker GB, Dursun SM, Hallak JEC. 2015. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res. 162:211–215.
32. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS., 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression:a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 13:71–82.
33. Mathews DC, Zarate CA., Jr. 2013. Current status of ketamine and related compounds for depression. J Clin Psychiatry. 74:516–517.
34. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW., 2014. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 45:693–704.
35. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD. 2014. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 23:243–254.
36. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, et al. 2013a. Antidepressant efficacy of ketamine in treatment-resistant major depression:a two-site randomized controlled trial. Am J Psychiatry. 170:1134–1142.
37. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. 2013b. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 74:250–256.
38. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA, Jr, Charney DS., 2014. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression:ketamine and other compounds. Annu Rev Pharmacol Toxicol. 54:119–139.
39. Owen RT., 2012. Glutamatergic approaches in major depressive disorder:focus on ketamine, memantine and riluzole. Drugs Today (Barc). 48:469–478.
40. Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S., 2013. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord. 147:431–436.
41. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M., 2010. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression:a case series. Pharmacopsychiatry. 43:33–35.
42. Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T., 2009. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression:report of two cases. World J Biol Psychiatry. 10:241–244.
43. Pochwat B, Palucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G., 2014. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs. 23:1181–1192.
44. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, GLYX-13 Clinical Study Group. 2015. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 21:140–149.
45. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. 2013. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol (Oxford). 27:444–450.
46. Salvadore G, Singh JB., 2013. Ketamine as a fast acting antidepressant:current knowledge and open questions. CNS Neurosci Ther. 19:428–436.
47. Sanacora G, Schatzberg AF., 2015. Ketamine:promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 40:259–267.
48. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. 2014. Lanicemine:a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 19:978–985.
49. Segmiller F, Ruther T, Linhardt A, Padberg F, Berger M, Pogarell O, Möller HJ, Kohler C, Schüle C. 2013. Repeated S-ketamine infusions in therapy resistant depression:a case series. J Clin Pharmacol. 53:996–998.
50. Serafini G, Howland RH, Rovedi F, Girardi P, Amore M., 2014. The role of ketamine in treatment-resistant depression:a systematic review. Curr Neuropharmacol. 12:444–461.
51. Singh J, Fedgchin M, Daly E, Xi L, Hulihan J, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, et al. 2014. Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-Resistant Depression:A Double-blind, Double-randomization, Placebo-controlled Phase 2a Study. 14th International Forum on Mood and Anxiety Disorders, 10-12 December, 2014. Vienna.
52. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ., 2013. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine:a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 74:966–973.
53. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T., 2013. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 34:287–293.
54. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA., 2013. Serotonergic drugs for depression and beyond. Curr Drug Targets. 14:578–585.
55. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. 2015. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 76:247–252.
56. WHO. 2012. RE:Depression Fact Sheet.
57. Zanicotti CG, Perez D, Glue P., 2012. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 15:400–403.
58. Zarate CA, Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA. 2013. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry. 74:257–264.
59. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006a. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63:856–864.
60. Zarate CA, Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. 2006b. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 163:153–155.
61. Zhang JC, Li SX, Hashimoto K., 2014. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 116:137–141.
62. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM., 2013. Ketamine:synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry. 18:1236–1241.